Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer

The Pharmacogenomics Journal volume 11, pages 375–382 (2011)Cite this article

Subjects

Abstract

Estrogen replacement therapy in women has shown a protective effect on the development of colonic carcinomas. Gender-related differences in the development of colonic carcinomas have also been reported. Estrogen receptor-β (ERβ) is expressed in colon carcinomas and has shown prognostic value in colon cancer patients. This study investigated an ERβ 3′ non-coding polymorphism associated with transcriptional activity to determine clinical outcome in patients with metastatic colon cancer. Genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 females, were collected from 1992 to 2003. These patients were analyzed for CA repeat polymorphism of the ERβ gene. Gender-related survival differences were associated with an ERβ (CA)n repeat polymorphism (P for interaction=0.003, the likelihood ratio test). Female patients with any short <22 (CA)n repeat alleles had shorter overall survival (OS) compared with female patients who had both long ⩾22 (CA)n repeat alleles. In the male patients, the opposite OS difference was found. This study supports the role of an ERβ (CA)n repeat polymorphism as a prognostic marker in metastatic colon cancer; however, this prognostic factor had opposite implications based on gender.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.

    Article  PubMed  Google Scholar 

  2. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398–2424.

    Article  CAS  PubMed  Google Scholar 

  3. DeCosse JJ, Ngoi SS, Jacobson JS, Cennerazzo WJ . Gender and colorectal cancer. Eur J Cancer Prev 1993; 2: 105–115.

    Article  CAS  PubMed  Google Scholar 

  4. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK . Cancer incidence and mortality, 1973-1995: a report card for the U.S.. Cancer 1998; 82: 1197–1207.

    Article  CAS  PubMed  Google Scholar 

  5. Gershbein LL . Action of estrogen and adrenocorticoids on adenocarcinoma induction by 1,2-dimethylhydrazine in male rats. Res Commun Chem Pathol Pharmacol 1993; 81: 117–120.

    CAS  PubMed  Google Scholar 

  6. Ochiai M, Watanabe M, Kushida H, Wakabayashi K, Sugimura T, Nagao M . DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. Carcinogenesis 1996; 17: 95–98.

    Article  CAS  PubMed  Google Scholar 

  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

    Article  CAS  Google Scholar 

  8. Grodstein F, Newcomb PA, Stampfer MJ . Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574–582.

    Article  CAS  PubMed  Google Scholar 

  9. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML . Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999; 261: 521–527.

    Article  CAS  PubMed  Google Scholar 

  10. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW . Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245–248.

    CAS  PubMed  Google Scholar 

  11. Jassam N, Bell SM, Speirs V, Quirke P . Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 2005; 14: 17–21.

    CAS  PubMed  Google Scholar 

  12. Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC . Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002; 174: 369–377.

    Article  CAS  PubMed  Google Scholar 

  13. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T . Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 2000; 161: 63–71.

    Article  CAS  PubMed  Google Scholar 

  14. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM . Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67: 2366–2372.

    Article  CAS  PubMed  Google Scholar 

  15. Caiazza F, Galluzzo P, Lorenzetti S, Marino M . 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun 2007; 359: 102–107.

    Article  CAS  PubMed  Google Scholar 

  16. Kennelly R, Kavanagh DO, Hogan AM, Winter DC . Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008; 9: 385–391.

    Article  CAS  PubMed  Google Scholar 

  17. Barone M, Tanzi S, Lofano K, Scavo MP, Guido R, Demarinis L et al. Estrogens, phytoestrogens and colorectal neoproliferative lesions. Genes Nutr 2008; 3: 7–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P . Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537–551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K . Functional analysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor beta gene. J Toxicol Sci 2008; 33: 237–240.

    Article  CAS  PubMed  Google Scholar 

  20. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2936–2942.

    Article  CAS  PubMed  Google Scholar 

  21. Lau HH, Ho AY, Luk KD, Kung AW . Estrogen receptor beta gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 2002; 31: 276–281.

    Article  CAS  PubMed  Google Scholar 

  22. Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001; 86: 2562–2568.

    CAS  PubMed  Google Scholar 

  23. Westberg L, Ho HP, Baghaei F, Nilsson S, Melke J, Rosmond R et al. Polymorphisms in oestrogen and progesterone receptor genes: possible influence on prolactin levels in women. Clin Endocrinol (Oxf) 2004; 61: 216–223.

    Article  CAS  PubMed  Google Scholar 

  24. Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006; 119: 2435–2442.

    Article  CAS  PubMed  Google Scholar 

  25. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I . Estrogen receptor beta (ESR2 ) polymorphisms and endometrial cancer (United States). Cancer Causes Control 2004; 15: 627–633.

    Article  PubMed  Google Scholar 

  26. Gebhardt F, Zanker KS, Brandt B . Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176–13180.

    Article  CAS  PubMed  Google Scholar 

  27. Berry G, Kitchin RM, Mock PA . A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 1991; 10: 749–755.

    Article  CAS  PubMed  Google Scholar 

  28. Rothman KJ . Modern Epidemiology. Lippincott-Raven: Philadelphia, 1998.

    Google Scholar 

  29. Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson JA et al. Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur J Hum Genet 2001; 9: 802–804.

    Article  CAS  PubMed  Google Scholar 

  30. Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN . Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 2004; 74: 501–508.

    Article  CAS  PubMed  Google Scholar 

  31. Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE et al. Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 2004; 19: 773–781.

    Article  CAS  PubMed  Google Scholar 

  32. Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M et al. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 2000; 269: 537–541.

    Article  CAS  PubMed  Google Scholar 

  33. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S . Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 2000; 45: 327–330.

    Article  CAS  PubMed  Google Scholar 

  34. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 7280–7287.

    Article  CAS  PubMed  Google Scholar 

  35. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S et al. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008; 68: 3037–3042.

    Article  CAS  PubMed  Google Scholar 

  36. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y . Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem 2007; 282: 10697–10706.

    Article  CAS  PubMed  Google Scholar 

  37. Levin ER . Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 17: 309–317.

    Article  CAS  PubMed  Google Scholar 

  38. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78–86.

    Article  CAS  PubMed  Google Scholar 

  39. Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G et al. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 2004; 69: 549–552.

    Article  CAS  PubMed  Google Scholar 

  40. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24: 3562–3569.

    Article  CAS  PubMed  Google Scholar 

  41. Janakiram NB, Steele VE, Rao CV . Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa) 2009; 2: 52–59.

    Article  CAS  Google Scholar 

  42. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009; 64: 51–59.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ivonne Villalobos for assistance with the preparation of this paper. This investigation was supported by grants from the National Institutes of Health (5 K24CA827540 and 5P30CA14089-271), the San Pedro Guild Research Fund and the Dhont Family Foundation. The research was carried out in the Sharon A Carpenter Laboratory at USC/Norris Comprehensive Cancer Center.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA

    O A Press, W Zhang, M A Gordon, M Azuma, S Iqbal & H-J Lenz

  2. Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA

    D Yang, C A Haiman & H-J Lenz

Authors
  1. O A Press
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M A Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C A Haiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H-J Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H-J Lenz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Press, O., Zhang, W., Gordon, M. et al. Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer. Pharmacogenomics J 11, 375–382 (2011). https://doi.org/10.1038/tpj.2010.45

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.45

Keywords

This article is cited by

Search

Advanced search

Quick links